ONCOLYTICS BIOTECH INC SEC Filings

Oncolytics Biotech Inc. has completed a two-step redomestication, moving its jurisdiction of incorporation from Alberta to British Columbia and then, on March 31, 2026, to Nevada, while keeping its name and Nasdaq listing under the ticker ONCY.

Each outstanding share automatically became one share of Nevada common stock with a $0.001 par value, and a new CUSIP (68237V 103) and ISIN (US68237V1035) now apply. The company adopted new Nevada Articles of Incorporation and Bylaws, entered into indemnification and advancement agreements with directors and executive officers, and designated Nevada and U.S. federal courts as exclusive forums for certain claims.

In connection with the move, the board approved a new 2026 Incentive Award Plan with 6,500,000 shares available plus additional shares from prior plans and an annual increase formula through 2036, while closing prior equity plans to new awards. New risk factors highlight that Nevada law and the governing documents may reduce stockholder rights and make corporate disputes and changes in control more difficult.

Oncolytics Biotech Inc. filed a shelf registration on Form S-3 to offer up to $250,000,000 of securities, including common stock, preferred stock, warrants, purchase contracts and units. The filing also re-registers $139.0 million of unsold securities from a prior Form F-3 under Rule 415(a)(6). The prospectus is a base shelf: specific terms, amounts and prices for each offering will be provided in future prospectus supplements.

Oncolytics Biotech Inc. files its annual report as a clinical-stage biotech focused on developing pelareorep, an intravenously delivered oncolytic virus immunotherapy for multiple cancers, especially gastrointestinal and breast tumors. The company has no approved products and does not expect significant revenue until pelareorep is commercialized.

Management discloses substantial doubt about its ability to continue as a going concern over the next 12 months, citing recurring losses and limited cash, and states that continued operations depend on raising additional capital. The filing details extensive clinical data, patent protection into at least 2031 with new applications potentially extending into the 2040s, and outlines intense competition and significant regulatory, financing, and execution risks, including an ongoing corporate domestication process from Canada to Nevada.

Oncolytics Biotech Inc. has completed the first step of its planned two-step redomestication by changing its jurisdiction of incorporation from Alberta to British Columbia, Canada, via a statutory continuance under the ABCA and BCBCA. Shareholders approved the continuance and subsequent U.S. domestication at a special meeting held on January 15, 2026.

All outstanding common shares remain outstanding as common shares of the British Columbia entity, with no change to the company’s name or Nasdaq ticker, which continues as ONCY. The current CUSIP (682310875) and ISIN (CA6823108759) remain in place until the expected second step, when the company plans to domesticate to Nevada on March 31, 2026. Effective April 1, 2026, the CUSIP is expected to change to 68237V103 and the ISIN to US68237V1035 while the stock continues trading on Nasdaq as common stock of a Nevada corporation.

Oncolytics Biotech Inc. reported that two new scientific abstracts featuring its investigational immunotherapy pelareorep have been accepted for presentation at the AACR 2026 Annual Meeting. The data come from the GOBLET study in metastatic pancreatic cancer and the AWARE-1 study in early-stage breast cancer.

GOBLET biomarker analyses suggest that adding pelareorep to atezolizumab and chemotherapy can shift pancreatic tumors toward a more immune-active state, with patients showing immune activation signatures experiencing longer progression-free survival and previously reported higher response rates than with chemotherapy alone. AWARE-1 data show pelareorep can drive coordinated anti-tumor immune responses and tertiary lymphoid structure formation, potentially turning immunologically “cold” breast tumors into more treatment-responsive “hot” tumors, supporting pelareorep as an immune-priming backbone for combination therapies across multiple tumor types.

Oncolytics Biotech Inc. director James T. Parsons reported an open-market purchase of 10,000 common shares of the company. The transaction took place at a price of $1.03 per share, indicating a direct cash investment in the stock. Following this trade, Parsons directly owns 41,849 common shares of Oncolytics Biotech Inc., reflecting an increased personal stake in the company’s equity.

Oncolytics Biotech Inc. chief executive officer Jared Kelly reported an open-market purchase of 5,050 common shares on March 12, 2026 at an average price of $0.96 per share. Following this transaction, he directly owns 114,050 common shares, indicating a modest increase in his personal stake.

Oncolytics Biotech Inc. filed an 8-K to highlight the launch of REO 033, a randomized Phase 2 study in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer. Patients will receive either standard bevacizumab plus FOLFIRI or an experimental combination adding pelareorep, with about 30 patients in each arm.

The primary goal is to measure objective response rate, with progression-free survival, overall survival, safety, and biomarker data as additional endpoints. The trial is sponsored by Oncolytics and led by Dr. Sanjay Goel at Rutgers Cancer Institute of New Jersey, with first sites expected to open soon and preliminary data targeted by the end of 2026.

The filing notes earlier REO 022 data in a similar population, where pelareorep-based therapy showed longer median survival and higher response rates than standard care, and that the pelareorep regimen recently received FDA Fast Track Designation in second-line KRAS-mutant MSS metastatic colorectal cancer.